Boston-based Seaport Therapeutics pulled off a bigger-than-expected Nasdaq debut on May 1, 2026, raising $254.9 million through nearly 14.2 million shares at $18 apiece. That was above the 11.8 million shares it had planned just days earlier. Underwriters still have an option for another 2.1 million shares, which would bring in roughly $38 million more. The company, focused on depression therapies, went public in the same week as Hemab Therapeutics, another biotech that overshot its target. Seaport CEO Daphne Zohar, who also co-founded Karuna Therapeutics before its $14 billion sale to Bristol Myers Squibb, described the IPO as a continuation of its growth rhythm, not a bid to sell out. She pointed to board addition Sharon Mates, the former Intra-Cellular Therapies CEO whose MDD drug Caplyta pulled in about $1.5 billion before Johnson & Johnson’s 2025 acquisition.
This decision to enter the market rather than join the M&A wave signals that part of biotech’s upper tier has regained access to public capital. That’s a shift from the dry 2023-2025 stretch when most exits came by acquisition. The scale of Seaport’s raise shows investor confidence returning to neuroscience, even after the March 2026 slowdown driven by Big Pharma dealmaking. In effect, public buyers appear prepared again to back late-stage psych programs on their own instead of waiting for the next takeover premium. And if this window stays open through midyear, other ready-to-list biotechs are likely watching the tape closely, considering a move while pricing leverage favors issuers over acquirers.
For investors, Seaport tests whether equity markets can sustain expensive neuropsychiatric launches without immediate pharma help. For payers, new self-commercializing antidepressants could upend contracting dynamics long shaped by incumbents with deeper rebates and bigger field forces. Should follow-on offerings hold, 2026 won’t just be a rebound year, it’ll look like a structural reopening of biotech equity. The data is early, but sentiment is turning. For anyone tracking reimbursement side pressures shaping mental-health pipelines, see RxPBM.ai. And quietly? It feels like the first real thaw the sector’s had in years.
